419 participants
A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma
- Study Type:
- INTERVENTIONAL
- Last Updated:
- 2026-08-31
- Start Date:
- 2020-06-12
- Completion:
- 2024-05-01
Conditions
- Multiple Myeloma
Interventions
- DRUG